Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

4 Jul 2017

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28687441
DOI: 10.1016/j.breast.2017.06.022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistancePMID 28687441Read ↗

The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistanceSemantic proximity Read ↗

New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistanceSemantic proximity Read ↗

Resistance to Anti-HER2 Therapies in Breast CancerSemantic proximity Read ↗

Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.Semantic proximity Read ↗

New agents for endocrine resistance in breast cancer.Semantic proximity Read ↗

Mechanisms of resistance to HER2 target therapy.Semantic proximity Read ↗

Drug resistance to targeted therapies: Déjà vu all over againSemantic proximity Read ↗

Response-based molecular subtyping—emergence of the third generation of breast cancer subtypesSemantic proximity Read ↗

Molecular basis for therapy resistanceSemantic proximity Read ↗

Pharmacogenomics of breast cancer therapy: An updateSemantic proximity Read ↗

Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.Semantic proximity Read ↗

Advances in systemic therapy for metastatic breast cancer: future perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.